Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1925 1
1926 1
1929 1
1941 1
1944 1
1945 2
1946 5
1947 6
1948 3
1949 1
1950 1
1951 2
1953 2
1955 3
1956 1
1957 3
1958 3
1959 2
1962 2
1964 1
1965 7
1966 2
1967 5
1968 2
1969 5
1970 4
1971 4
1972 5
1973 3
1974 1
1975 3
1976 1
1977 4
1978 4
1979 4
1980 4
1981 4
1982 2
1983 1
1984 5
1985 8
1986 4
1987 13
1988 3
1989 9
1990 3
1991 6
1992 7
1993 7
1994 12
1995 18
1996 21
1997 17
1998 18
1999 22
2000 27
2001 27
2002 28
2003 35
2004 46
2005 31
2006 24
2007 34
2008 38
2009 47
2010 46
2011 59
2012 60
2013 54
2014 49
2015 57
2016 52
2017 39
2018 37
2019 54
2020 46
2021 61
2022 44
2023 38
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

1,217 results

Results by year

Filters applied: . Clear all
Page 1
Alpha1-antitrypsin improves survival in murine abdominal sepsis model by decreasing inflammation and sequestration of free heme.
Zemtsovski JD, Tumpara S, Schmidt S, Vijayan V, Klos A, Laudeley R, Held J, Immenschuh S, Wurm FM, Welte T, Haller H, Janciauskiene S, Shushakova N. Zemtsovski JD, et al. Among authors: haller h. Front Immunol. 2024 Mar 18;15:1368040. doi: 10.3389/fimmu.2024.1368040. eCollection 2024. Front Immunol. 2024. PMID: 38562925 Free PMC article.
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.
Tuttle KR, Hauske SJ, Canziani ME, Caramori ML, Cherney D, Cronin L, Heerspink HJL, Hugo C, Nangaku M, Rotter RC, Silva A, Shah SV, Sun Z, Urbach D, de Zeeuw D, Rossing P; ASi in CKD group. Tuttle KR, et al. Lancet. 2024 Jan 27;403(10424):379-390. doi: 10.1016/S0140-6736(23)02408-X. Epub 2023 Dec 15. Lancet. 2024. PMID: 38109916 Clinical Trial.
Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD.
Mayne KJ, Staplin N, Keane DF, Wanner C, Brenner S, Cejka V, Stegbauer J, Judge PK, Preiss D, Emberson J, Trinca D, Dayanandan R, Lee R, Nolan J, Omata A, Green JB, Cherney DZI, Hooi LS, Pontremoli R, Tuttle KR, Lees JS, Mark PB, Davies SJ, Hauske SJ, Steubl D, Brückmann M, Landray MJ, Baigent C, Haynes R, Herrington WG; EMPA-KIDNEY Collaborative Group. Mayne KJ, et al. J Am Soc Nephrol. 2024 Feb 1;35(2):202-215. doi: 10.1681/ASN.0000000000000271. Epub 2023 Dec 12. J Am Soc Nephrol. 2024. PMID: 38082486 Free PMC article. Clinical Trial.
1,217 results